Improved Formulations to Enhance Bio-availability for Antisense Therapeutics

Award Information
Agency:
Department of Defense
Branch
Office for Chemical and Biological Defense
Amount:
$70,000.00
Award Year:
2010
Program:
SBIR
Phase:
Phase I
Contract:
HDTRA1-10-P-0041
Award Id:
96627
Agency Tracking Number:
C101-102-0079
Solicitation Year:
n/a
Solicitation Topic Code:
CBD 10-102
Solicitation Number:
n/a
Small Business Information
4701 Innovation Drive, Lincoln, NE, 68521
Hubzone Owned:
N
Minority Owned:
N
Woman Owned:
N
Duns:
131068186
Principal Investigator:
Luis Nunez
Chief Technology Officers
(630) 854-8173
luisteo@aol.com
Business Contact:
Gus Larsen
CEO
(402) 416-1811
lnkchemsolutions@aim.com
Research Institute:
n/a
Abstract
In general, many biological and chemical agents affect the lungs directly or indirectly, even if the respiratory system is not the primary target organ of a military or terrorist attack. Both in the case of military and civilian attacks the lung can be one of the first organs affected by a chemical or biological agent. LNK Chemsolutions (LNK) with expertise in nanoparticle formulations and the University of Illinois Chicago with expertise in Acute Lung Injury (ALI) molecular biology and treatment modality development have teamed up to develop novel oral and inhalation formulation of targeted nanoparticles (NPs) containing siRNA and/or miRNA to improve the treatment of ALI unobtainable with current delivery systems.

* information listed above is at the time of submission.

Agency Micro-sites


SBA logo

Department of Agriculture logo

Department of Commerce logo

Department of Defense logo

Department of Education logo

Department of Energy logo

Department of Health and Human Services logo

Department of Homeland Security logo

Department of Transportation logo

Enviromental Protection Agency logo

National Aeronautics and Space Administration logo

National Science Foundation logo
US Flag An Official Website of the United States Government